Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Consensus Report of the 4th International Forum for Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid Magnetic Resonance Imaging

  • Lee, Jeong-Min (Department of Radiology, Seoul National University College of Medicine) ;
  • Zech, Christoph J. (Institute of Clinical Radiology, University Hospitals Munich) ;
  • Bolondi, Luigi (Department of Digestive Diseases and Internal Medicine, St. Orsola-Malpighi University Hospital) ;
  • Jonas, Eduard (Division of Surgery, Karolinska Institute Danderyds Sjukhus) ;
  • Kim, Myeong-Jin (Department of Radiology, Yonsei University College of Medicine) ;
  • Matsui, Osamu (Department of Radiology, Kanazawa University, Graduate School of Medical Science) ;
  • Merkle, Elmar M. (Department of Radiology and Head of MRI, Duke University) ;
  • Sakamoto, Michiie (Departmentof Pathology Graduate School of Medicine, Keio University School of Medicine) ;
  • Choi, Byung-Ihn (Department of Radiology, Seoul National University College of Medicine)
  • Published : 2011.08.01
⟨ Previous Next ⟩

Abstract

This paper reports on issues relating to the optimal use of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid magnetic resonance imaging (Gd-EOB-DTPA MR imaging) together with the generation of consensus statements from a working group meeting, which was held in Seoul, Korea (2010). Gd-EOB-DTPA has been shown to improve the detection and characterization of liver lesions, and the information provided by the hepatobiliary phase is proving particularly useful in differential diagnoses and in the characterization of small lesions (around 1-1.5 cm). Discussion also focused on advances in the role of organic anion-transporting polypeptide 8 (OATP8) transporters. Gd-EOB-DTPA is also emerging as a promising tool for functional analysis, enabling the calculation of post-surgical liver function in the remaining segments. Updates to current algorithms were also discussed.

Keywords

References

  1. Liver Cancer Incidence and Mortality Worldwide in 2008 Summary. Available at: http://globocan.iarc.fr/factsheets/cancers/liver.asp. Last accessed December 13, 2010
  2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108 https://doi.org/10.3322/canjclin.55.2.74
  3. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 2004;14:559-578 https://doi.org/10.1007/s00330-004-2236-1
  4. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005;40:715-724 https://doi.org/10.1097/01.rli.0000184756.66360.d3
  5. Shuter B, Tofts PS, Wang SC, Pope JM. The relaxivity of Gd-EOB-DTPA and Gd-DTPA in liver and kidney of the Wistar rat. Magn Reson Imaging 1996;14:243-253 https://doi.org/10.1016/0730-725X(95)02097-D
  6. Vander Elst L, Maton F, Laurent S, Seghi F, Chapelle F, Muller RN. A multinuclear MR study of Gd-EOB-DTPA: comprehensive preclinical characterization of an organ specific MRI contrast agent. Magn Reson Med 1997;38:604-614 https://doi.org/10.1002/mrm.1910380415
  7. Kitao A, Zen Y, Matsui O, Gabata T, Kobayashi S, Koda W, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features. Radiology 2010;256:817-826 https://doi.org/10.1148/radiol.10092214
  8. Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009;44:793-798 https://doi.org/10.1007/s00535-009-0056-4
  9. Bartolozzi C, Crocetti L, Lencioni R, Cioni D, Della Pina C, Campani D. Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol 2007;17:2519-2530 https://doi.org/10.1007/s00330-007-0602-5
  10. International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658-664 https://doi.org/10.1002/hep.22709
  11. Kojiro M, Nakashima O. Histopathologic evaluation of hepatocellular carcinoma with special reference to small early stage tumors. Semin Liver Dis 1999;19:287-296 https://doi.org/10.1055/s-2007-1007118
  12. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Yamamoto J, Shimada K, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 1998;28:1241-1246 https://doi.org/10.1002/hep.510280511
  13. Sakamoto M, Effendi K, Masugi Y. Molecular diagnosis of multistage hepatocarcinogenesis. Jpn J Clin Oncol 2010;40:891-896 https://doi.org/10.1093/jjco/hyq099
  14. Oikawa T, Ojima H, Yamasaki S, Takayama T, Hirohashi S, Sakamoto M. Multistep and multicentric development of hepatocellular carcinoma: histological analysis of 980 resected nodules. J Hepatol 2005;42:225-229
  15. Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991;22:172-178 https://doi.org/10.1016/0046-8177(91)90039-R
  16. Sakamoto M, Hirohashi S. Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection. Jpn J Clin Oncol 1998;28:604-608 https://doi.org/10.1093/jjco/28.10.604
  17. Kudo M. The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol 2010;25:439-452 https://doi.org/10.1111/j.1440-1746.2009.06207.x
  18. Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 2003;33 Suppl 2:1-5
  19. Konig J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000;275:23161-23168 https://doi.org/10.1074/jbc.M001448200
  20. Vavricka SR, Jung D, Fried M, Grutzner U, Meier PJ, Kullak-Ublick GA. The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J Hepatol 2004;40:212-218 https://doi.org/10.1016/j.jhep.2003.10.008
  21. Tsuda N, Matsui O. Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculi--gadoxetic acid-enhanced MR imaging. Radiology 2010;256:767-773 https://doi.org/10.1148/radiol.10092065
  22. Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, Fraquelli M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010;59:638-644 https://doi.org/10.1136/gut.2009.187286
  23. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236 https://doi.org/10.1002/hep.20933
  24. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022 https://doi.org/10.1002/hep.24199
  25. Clinical Practice Guidelines for Hepatocellular Carcinoma - The Japan Society of Hepatology 2009 update. Hepatol Res 2010;40 Suppl 1:2-144 https://doi.org/10.1111/j.1872-034X.2010.00650.x
  26. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008;134:1752-1763 https://doi.org/10.1053/j.gastro.2008.02.090
  27. Lee JM, Kim SJ, Kim SH, Kim KW, Lee JY, Han JK, et al. Enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced MR imaging in the cirrhotic liver: comparison with multiphasic liver CT. RSNA 2009 Abstract no. SSA07-07
  28. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010;255:459-466 https://doi.org/10.1148/radiol.10091388
  29. Di Martino M, Marin D, Guerrisi A, Baski M, Galati F, Rossi M, et al. Intraindividual comparison of gadoxetate disodiumenhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. Radiology 2010;256:806-816 https://doi.org/10.1148/radiol.10091334
  30. Ichikawa T, Saito K, Yoshioka N, Tanimoto A, Gokan T, Takehara Y, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 2010;45:133-141 https://doi.org/10.1097/RLI.0b013e3181caea5b
  31. Marin D, Di Martino M, Guerrisi A, De Filippis G, Rossi M, Ginanni Corradini S, et al. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. Radiology 2009;251:85-95 https://doi.org/10.1148/radiol.2511080400
  32. Sun HY, Lee JM, Shin CI, Lee DH, Moon SK, Kim KW, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or = 2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 2010;45:96-103 https://doi.org/10.1097/RLI.0b013e3181c5faf7
  33. Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Muhi A, et al. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 2010;256:151-158 https://doi.org/10.1148/radiol.10091885
  34. Tajima T, Honda H, Taguchi K, Asayama Y, Kuroiwa T, Yoshimitsu K, et al. Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation. AJR Am J Roentgenol 2002;178:885-897 https://doi.org/10.2214/ajr.178.4.1780885
  35. Kogita S, Imai Y, Okada M, Kim T, Onishi H, Takamura M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 2010;20:2405-2413 https://doi.org/10.1007/s00330-010-1812-9
  36. Boutros C, Katz SC, Espat NJ. Management of an incidental liver mass. Surg Clin North Am 2010;90:699-718 https://doi.org/10.1016/j.suc.2010.04.005
  37. Marin D, Furlan A, Federle MP, Midiri M, Brancatelli G. Imaging approach for evaluation of focal liver lesions. Clin Gastroenterol Hepatol 2009;7:624-634 https://doi.org/10.1016/j.cgh.2009.03.024
  38. Chamberlain RS, Jarnagin WR, DeCorato D. Incidentally discovered hepatic lesions. In: Steele GD, Phillips TL, Chabner BA, eds. Hepatobiliary Cancer. Hamilton, London: American Cancer Society Atlas of Clinical Oncology, 2001:31-42
  39. Zech CJ, Grazioli L, Jonas E, Ekman M, Niebecker R, Gschwend S, et al. Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden. Eur Radiol 2009;19 Suppl 3:S753-763 https://doi.org/10.1007/s00330-009-1432-4
  40. Assy N, Nasser G, Djibre A, Beniashvili Z, Elias S, Zidan J. Characteristics of common solid liver lesions and recommendations for diagnostic workup. World J Gastroenterol 2009;15:3217-3227 https://doi.org/10.3748/wjg.15.3217
  41. Soussan M, Aube C, Bahrami S, Boursier J, Valla DC, Vilgrain V. Incidental focal solid liver lesions: diagnostic performance of contrast-enhanced ultrasound and MR imaging. Eur Radiol 2010;20:1715-1725 https://doi.org/10.1007/s00330-009-1700-3
  42. Little JM, Richardson A, Tait N. Hepatic dystychoma: a five year experience. HPB Surg 1991;4:291-297 https://doi.org/10.1155/1991/96304
  43. Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPAenhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 2008;43:504-511 https://doi.org/10.1097/RLI.0b013e3181705cd1
  44. Kamaya A, Maturen KE, Tye GA, Liu YI, Parti NN, Desser TS. Hypervascular liver lesions. Semin Ultrasound CT MR 2009;30:387-407 https://doi.org/10.1053/j.sult.2009.06.001
  45. Allaire GS, Rabin L, Ishak KG, Sesterhenn IA. Bile duct adenoma. A study of 152 cases. Am J Surg Pathol 1988;12:708-715 https://doi.org/10.1097/00000478-198809000-00007
  46. Bhathal PS, Hughes NR, Goodman ZD. The so-called bile duct adenoma is a peribiliary gland hamartoma. Am J Surg Pathol 1996;20:858-864 https://doi.org/10.1097/00000478-199607000-00009
  47. Tajima T, Honda H, Kuroiwa T, Yoshimitsu K, Irie H, Aibe H, et al. Radiologic features of intrahepatic bile duct adenoma: a look at the surface of the liver. J Comput Assist Tomogr 1999;23:690-695 https://doi.org/10.1097/00004728-199909000-00008
  48. Lordan JT, Karanjia ND, Quiney N, Fawcett WJ, Worthington TR. A 10-year study of outcome following hepatic resection for colorectal liver metastases - The effect of evaluation in a multidisciplinary team setting. Eur J Surg Oncol 2009;35:302-306 https://doi.org/10.1016/j.ejso.2008.01.028
  49. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 2007;11:1057-1077 https://doi.org/10.1007/s11605-006-0061-3
  50. Nordlinger B, Van Cutsem E, Rougier P, Kohne CH, Ychou M, Sobrero A, et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007;43:2037-2045 https://doi.org/10.1016/j.ejca.2007.07.017
  51. Ahmad A, Chen SL, Bilchik AJ. Role of repeated hepatectomy in the multimodal treatment of hepatic colorectal metastases. Arch Surg 2007;142:526-531; discussion 531-522 https://doi.org/10.1001/archsurg.142.6.526
  52. Kornprat P, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 2007;14:1151-1160 https://doi.org/10.1245/s10434-006-9068-y
  53. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748-756 https://doi.org/10.1148/radiol.2243011362
  54. Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis. Radiology 2005;237:123-131 https://doi.org/10.1148/radiol.2371042060
  55. Marcos A, Ham JM, Fisher RA, Olzinski AT, Posner MP. Surgical management of anatomical variations of the right lobe in living donor liver transplantation. Ann Surg 2000;231:824-831 https://doi.org/10.1097/00000658-200006000-00006
  56. Catalano OA, Singh AH, Uppot RN, Hahn PF, Ferrone CR, Sahani DV. Vascular and biliary variants in the liver: implications for liver surgery. Radiographics 2008;28:359-378 https://doi.org/10.1148/rg.282075099
  57. Kawarada Y, Das BC, Taoka H. Anatomy of the hepatic hilar area: the plate system. J Hepatobiliary Pancreat Surg 2000;7:580-586 https://doi.org/10.1007/s005340070007
  58. Uchida K, Taniguchi M, Shimamura T, Suzuki T, Yamashita K, Ota M, et al. Three-dimensional computed tomography scan analysis of hepatic vasculatures in the donor liver for living donor liver transplantation. Liver Transpl 2010;16:1062-1068 https://doi.org/10.1002/lt.22109
  59. Scatton O, Plasse M, Dondero F, Vilgrain V, Sauvanet A, Belghiti J. Impact of localized congestion related to venous deprivation after hepatectomy. Surgery 2008;143:483-489 https://doi.org/10.1016/j.surg.2007.11.002
  60. Radtke A, Sotiropoulos GC, Sgourakis G, Molmenti EP, Schroeder T, Saner FH, et al. Hepatic venous drainage: how much can we learn from imaging studies? Anatomic-functional classification derived from three-dimensional computed tomography reconstructions. Transplantation 2010;89:1518-1525 https://doi.org/10.1097/TP.0b013e3181dd6bac
  61. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000;191:38-46 https://doi.org/10.1016/S1072-7515(00)00261-1
  62. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002;236:397-406; discussion 406-397 https://doi.org/10.1097/00000658-200210000-00001
  63. Clavien PA, Oberkofler CE, Raptis DA, Lehmann K, Rickenbacher A, El-Badry AM. What is critical for liver surgery and partial liver transplantation: size or quality? Hepatology 2010;52:715-729 https://doi.org/10.1002/hep.23713
  64. Fotbolcu H, Yakar T, Duman D, Karaahmet T, Tigen K, Cevik C, et al. Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol J 2010;17:457-463
  65. Gazzaniga GM, Cappato S, Belli FE, Bagarolo C, Filauro M. Assessment of hepatic reserve for the indication of hepatic resection: how I do it. J Hepatobiliary Pancreat Surg 2005;12:27-30 https://doi.org/10.1007/s00534-004-0946-z
  66. Morris-Stiff G, Gomez D, Prasad R. Quantitative assessment of hepatic function and its relevance to the liver surgeon. J Gastrointest Surg 2009;13:374-385 https://doi.org/10.1007/s11605-008-0564-1
  67. Jonas E, Hultcrantz R, Slezak P, Blomqvist L, Schnell PO, Jacobsson H. Dynamic 99Tcm-HIDA SPET: non-invasive measuring of intrahepatic bile flow. Description of the method and a study in primary sclerosing cholangitis. Nucl Med Commun 2001;22:127-134 https://doi.org/10.1097/00006231-200102000-00003
  68. Harbin WP, Robert NJ, Ferrucci JT Jr. Diagnosis of cirrhosis based on regional changes in hepatic morphology: a radiological and pathological analysis. Radiology 1980;135:273-283 https://doi.org/10.1148/radiology.135.2.7367613
  69. Garcia JE, Atkins F. A low right-to-left hepatic lobe ratio. Is streamlining of ethanol to the right lobe of the liver the cause? Clin Nucl Med 1985;10:807-809 https://doi.org/10.1097/00003072-198511000-00014
  70. Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, Aouizerat BE, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006;44:874-880 https://doi.org/10.1002/hep.21346
  71. Nilsson H, Nordell A, Vargas R, Douglas L, Jonas E, Blomqvist L. Assessment of hepatic extraction fraction and input relative blood flow using dynamic hepatocyte-specific contrastenhanced MRI. J Magn Reson Imaging 2009;29:1323-1331 https://doi.org/10.1002/jmri.21801
  72. Jacobsson H, Jonas E, Hellstrom PM, Larsson SA. Different concentrations of various radiopharmaceuticals in the two main liver lobes: a preliminary study in clinical patients. J Gastroenterol 2005;40:733-738 https://doi.org/10.1007/s00535-005-1617-9
  73. Nilsson H, Blomqvist L, Douglas L, Nordell A, Jonas E. Assessment of liver function in primary biliary cirrhosis using Gd-EOB-DTPA-enhanced liver MRI. HPB (Oxford) 2010;12:567-576 https://doi.org/10.1111/j.1477-2574.2010.00223.x

Cited by

  1. Gadoxetic acid-enhanced MRI: a method for the detection of hepatic metastases vol.4, pp.3, 2011, https://doi.org/10.2217/iim.12.22
  2. Histological characteristics of small hepatocellular carcinomas showing atypical enhancement patterns on gadoxetic acid‐enhanced MR imaging vol.37, pp.6, 2013, https://doi.org/10.1002/jmri.23940
  3. Gadoxetic acid‐enhanced MRI with MR cholangiography for the preoperative evaluation of bile duct cancer vol.38, pp.1, 2013, https://doi.org/10.1002/jmri.23957
  4. Impact of gadoxetic acid (Gd‐EOB‐DTPA)‐enhanced magnetic resonance on the non‐invasive diagnosis of small hepatocellular carcinoma: a prospective study vol.37, pp.3, 2011, https://doi.org/10.1111/apt.12166
  5. Consensus report of the Fifth International Forum for Liver MRI. vol.201, pp.1, 2011, https://doi.org/10.2214/ajr.12.9491
  6. Diffusion-Weighted MRI in Intrahepatic Bile Duct Adenoma Arising from the Cirrhotic Liver vol.14, pp.5, 2011, https://doi.org/10.3348/kjr.2013.14.5.769
  7. MR Imaging in Patients with Suspected Liver Metastases: Value of Liver-Specific Contrast Agent Gadoxetic Acid vol.14, pp.6, 2011, https://doi.org/10.3348/kjr.2013.14.6.894
  8. Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring vol.12, pp.3, 2011, https://doi.org/10.1102/1470-7330.2012.0044
  9. The Proper Scan Delay of the Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging to Evaluate Small-Sized (≤ 3 cm) Hepatocellular Carcinoma in Cirrhotic Liver vol.68, pp.4, 2011, https://doi.org/10.3348/jksr.2013.68.4.319
  10. The Effect of Gd-EOB-DPTA on the Stiffness Value of Magnetic Resonance Elastography in Evaluating Hepatic Fibrosis vol.17, pp.3, 2011, https://doi.org/10.13104/jksmrm.2013.17.3.215
  11. Imaging bile duct tumors: pathologic concepts, classification, and early tumor detection vol.38, pp.6, 2013, https://doi.org/10.1007/s00261-013-0027-3
  12. Usefulness of MR elastography for predicting esophageal varices in cirrhotic patients vol.39, pp.3, 2011, https://doi.org/10.1002/jmri.24186
  13. Small (<or=1-cm) Hepatocellular Carcinoma: Diagnostic Performance and Imaging Features at Gadoxetic Acid-enhanced MR Imaging vol.271, pp.3, 2011, https://doi.org/10.1148/radiol.14131996
  14. Gadoxetic acid-enhanced MRI for T-staging of gallbladder carcinoma: emphasis on liver invasion vol.87, pp.1033, 2014, https://doi.org/10.1259/bjr.20130608
  15. Local Recurrence After Chemoembolization of Hepatocellular Carcinoma: Uptake of Gadoxetic Acid as a New Prognostic Factor vol.202, pp.4, 2011, https://doi.org/10.2214/ajr.13.10848
  16. High Spatial Resolution, Respiratory-Gated, T1-Weighted Magnetic Resonance Imaging of the Liver and the Biliary Tract During the Hepatobiliary Phase of Gadoxetic Acid–Enhanced Magnetic Resonance vol.38, pp.3, 2011, https://doi.org/10.1097/rct.0000000000000055
  17. High-resolution T1-weighted gradient echo imaging for liver MRI using parallel imaging at high-acceleration factors vol.39, pp.4, 2011, https://doi.org/10.1007/s00261-014-0099-8
  18. Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI vol.6, pp.7, 2011, https://doi.org/10.4254/wjh.v6.i7.477
  19. The role of MRI using liver-specific contrast agent in the assessment of focal liver lesion vol.47, pp.5, 2011, https://doi.org/10.1590/0100-3984.2014.47.5e2
  20. State of the art: hepatocellular carcinoma vol.10, pp.15, 2011, https://doi.org/10.2217/fon.14.215
  21. Navigated three-dimensional T1-weighted gradient-echo sequence for gadoxetic acid liver magnetic resonance imaging in patients with limited breath-holding capacity vol.40, pp.2, 2011, https://doi.org/10.1007/s00261-014-0214-x
  22. Differentiation of lipid poor angiomyolipoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging vol.40, pp.3, 2015, https://doi.org/10.1007/s00261-014-0244-4
  23. Diagnosing Borderline Hepatic Nodules in Hepatocarcinogenesis: Imaging Performance vol.205, pp.1, 2015, https://doi.org/10.2214/ajr.14.12655
  24. Usefulness of two-point Dixon fat-water separation technique in gadoxetic acid-enhanced liver magnetic resonance imaging. vol.21, pp.16, 2015, https://doi.org/10.3748/wjg.v21.i16.5017
  25. Assessing liver function in patients with HBV-related HCC: a comparison of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging with DWI vol.25, pp.5, 2011, https://doi.org/10.1007/s00330-014-3542-x
  26. Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome vol.7, pp.9, 2011, https://doi.org/10.4254/wjh.v7.i9.1157
  27. Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? vol.25, pp.10, 2011, https://doi.org/10.1007/s00330-015-3686-3
  28. Early Detection of Hepatocellular Carcinoma: How to Screen and Follow up Patients with Liver Cirrhosis According to the GERMAN S3 Guideline? vol.5, pp.4, 2015, https://doi.org/10.3390/diagnostics5040497
  29. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging vol.26, pp.6, 2011, https://doi.org/10.1007/s00330-015-4005-8
  30. Health economic evaluation of Gd-EOB-DTPA MRI vs ECCM-MRI and multi-detector computed tomography in patients with suspected hepatocellular carcinoma in Thailand and South Korea vol.19, pp.8, 2011, https://doi.org/10.3111/13696998.2016.1171230
  31. FLAIR in Gd-EOB-DTPA Enhanced MRI: Does It Make a Difference? vol.7, pp.2, 2011, https://doi.org/10.4236/ojrad.2017.72015
  32. Diagnostic Accuracy of Gd-EOB-DTPA for Detection Hepatocellular Carcinoma (HCC): A Comparative Study with Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) and Dynamic Contrast Enhanced Compu vol.82, pp.None, 2017, https://doi.org/10.12659/pjr.899239
  33. A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function vol.13, pp.5, 2011, https://doi.org/10.1371/journal.pone.0197213
  34. The capsule appearance of hepatocellular carcinoma in gadoxetic acid-enhanced MR imaging : Correlation with pathology and dynamic CT vol.97, pp.25, 2011, https://doi.org/10.1097/md.0000000000011142
  35. Gd-EOB-DTPA dynamic contrast-enhanced magnetic resonance imaging is more effective than enhanced 64-slice CT for the detection of small lesions in patients with hepatocellular carcinoma vol.97, pp.52, 2011, https://doi.org/10.1097/md.0000000000013964
  36. Liver Functional Evaluation Using Gadoxetic Acid Versus the Gold Standard Hepatobiliary Scintigraphy in Patients with Bile Duct Diseases vol.100, pp.4, 2011, https://doi.org/10.20862/0042-4676-2019-100-4-200-208
  37. Added Value of Contrast Medium in Whole-Body Hybrid Positron Emission Tomography/Magnetic Resonance Imaging: Comparison between Contrast-Enhanced and Non-Contrast-Enhanced Protocols vol.29, pp.1, 2011, https://doi.org/10.1159/000501497
  38. Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging vol.30, pp.1, 2020, https://doi.org/10.1007/s00330-019-06369-4